SCHEMBL1100178

SCHEMBL1100178

CCN(CC1NC(=O)NC1=O)S(=O)(=O)c1ccc(Oc2ccc(C)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.53
HTT P42858 6/20 0.53
SMN1; SMN2 Q16637 6/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
CNR2 P34972 4/20 0.39
NR3C1 P04150 1/20 0.39
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
ALDH1A1 P00352 2/20 0.38
CNR1 P21554 1/20 0.38
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1108509 1.00 LMNA (0.53) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1101103 0.91 LMNA (0.53) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1108504 0.91 LMNA (0.53) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1101147 0.91 LMNA (0.53) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1108551 0.91 LMNA (0.53) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1098805 0.90 LMNA (0.52) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1108499 0.90 LMNA (0.52) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1098869 0.89 SMN1; SMN2 (0.51) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1108566 0.89 SMN1; SMN2 (0.51) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1100232 0.87 HTT (0.49) LMNAHTTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 US disclosed
EP-1370537-B1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2010-10-13 EP disclosed
US-7666892-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2010-02-23 US disclosed
US-20080262045-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-10-23 US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 US disclosed
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 US disclosed
EP-1370537-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074751-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273849-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 LMNA 2791/4885HTT 3958/4885SMN1; SMN2 1262/4885
US-20080262045-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 LMNA 2791/4885HTT 3958/4885SMN1; SMN2 1262/4885
US-20040138276-A1 Metalloproteinase inhibitors MMP9, MMP11, MMP7 LMNA 2081/4885HTT 4646/4885SMN1; SMN2 1982/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 LMNA 2465/4885HTT 4139/4885SMN1; SMN2 2809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.